Geode Capital Management LLC Has $4.08 Billion Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Geode Capital Management LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,857,385 shares of the medical research company’s stock after buying an additional 197,442 shares during the quarter. Geode Capital Management LLC owned approximately 2.05% of Thermo Fisher Scientific worth $4,075,540,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of TMO. HighPoint Advisor Group LLC raised its position in Thermo Fisher Scientific by 0.4% in the 4th quarter. HighPoint Advisor Group LLC now owns 11,949 shares of the medical research company’s stock valued at $6,491,000 after purchasing an additional 53 shares during the last quarter. Family Legacy Inc. lifted its position in Thermo Fisher Scientific by 5.8% during the 4th quarter. Family Legacy Inc. now owns 2,664 shares of the medical research company’s stock worth $1,452,000 after buying an additional 147 shares in the last quarter. Rodgers Brothers Inc. grew its holdings in Thermo Fisher Scientific by 1.8% during the 4th quarter. Rodgers Brothers Inc. now owns 2,119 shares of the medical research company’s stock worth $1,102,000 after acquiring an additional 37 shares during the last quarter. Seven Mile Advisory raised its stake in shares of Thermo Fisher Scientific by 23.2% in the fourth quarter. Seven Mile Advisory now owns 696 shares of the medical research company’s stock worth $362,000 after acquiring an additional 131 shares during the last quarter. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $93,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO opened at $498.05 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market capitalization of $187.89 billion, a price-to-earnings ratio of 30.13, a P/E/G ratio of 2.99 and a beta of 0.79. The business’s 50-day moving average price is $540.37 and its two-hundred day moving average price is $551.02. Thermo Fisher Scientific Inc. has a 1 year low of $484.27 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Wells Fargo & Company upped their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a report on Friday, January 31st. Scotiabank boosted their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday, February 3rd. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.